Brève description de l’étude (Source de données: BASEC)
Si tratta di uno studio di fase 2 multicentrico. L’obiettivo dello studio consiste nel valutare gli effetti di BIIB033 rispetto al placebo sul miglioramento dell’invalidità nell’arco di 72 settimane e sulle misure aggiuntive del miglioramento dell’invalidità.
Maladies étudiées(Source de données: BASEC)
Sclerosi multipla (SM)
Health conditions
(Source de données: WHO)
Multiple Sclerosis
Maladie rare
(Source de données: BASEC)
Non
Intervention étudiée (p. ex., médicament, thérapie, campagne)
(Source de données: BASEC)
infusioni EV di 750 mg di BIIB033 o placebo ogni 4 settimane
Interventions
(Source de données: WHO)
Drug: BIIB033 (opicinumab);Drug: Placebo
Critères de participation à l’étude
(Source de données: BASEC)
• età compresa tra 18 e 58 anni
• diagnosi di sclerosi multipla recidivante con un’EDSS compreso tra 2,0 e 6,0
• dose stabile di una terapia antinfiammatoria modificanti la malattia per almeno 24 settimane
Critères d’exclusion
(Source de données: BASEC)
• sclerosi multipla primaria progressiva
• recente ricidiva
• se non può eseguire la risonanza magnetica
Inclusion/Exclusion Criteria
(Source de données: WHO)
Key Inclusion Criteria: Part 1
- Baseline Expanded Disability Status Scale (EDSS) of 2.0 to 6.0, have a diagnosis of
relapsing-remitting multiple sclerosis (RRMS) per the 2010 McDonald's criteria or
onset of secondary progressive multiple sclerosis (SPMS) per the Lublin and Reingold
criteria, and should have experienced their first MS symptom(s) within the previous 20
years.
- Subjects must have experienced at least 1 of the following within 24 months prior to
Day 1/Baseline: a clinical relapse (but not within 24 weeks prior to Day 1/Baseline),
gadolinium-enhancing lesions on brain or spinal cord magnetic resonance imaging (MRI),
or new T2 lesion(s) on brain or spinal cord MRI.
- Subjects must be on a stable dose of a protocol-specified anti-inflammatory
disease-modifying therapy (DMT) (IFNß [Avonex, Plegridy, Betaferon/Betaseron, or
Rebif], dimethyl fumarate (DMF) [Tecfidera], or natalizumab [Tysabri]) for at least 24
weeks prior to enrollment.
- In addition, subjects must have met protocol-defined MRI characteristics using
magnetization transfer ratio (MTR) and diffusion tensor imaging (DTI) sequences at
Screening/Baseline.
Key Inclusion Criteria: Part 2
-Subjects who complete study treatment (BIIB033 or placebo) at Part 1/Week 72 Visit.
Key Exclusion Criteria: Part 1
- Primary progressive MS
- An MS relapse that has occurred within 24 weeks prior to Day 1/Baseline or the subject
has not stabilized from a previous relapse at the time of Screening.
- Treatment with any chemotherapeutic agents (e.g., mitoxantrone, cyclophosphamide,
cladribine), cell-depleting monoclonal antibodies (mAbs) (e.g., rituximab,
ocrelizumab, alemtuzumab), total lymphoid irradiation, T-cell or T-cell receptor
vaccination, or teriflunomide within 1 year prior to Day 1/Baseline.
- Treatment with other anti-inflammatory DMTs (e.g., GA, fingolimod, daclizumab) or
plasmapheresis within 24 weeks prior to Day1/Baseline.
- Treatment with Botox for limb spasticity within 24 weeks before Day 1/Baseline.
- Contraindications to MRI, for example, presence of pacemakers or other implanted metal
devices (excluding dental braces), an allergy to gadolinium renal impairment, or
claustrophobia that cannot be medically managed.
- History of human immunodeficiency virus or other immunodeficient conditions.
- History of malignancy; however, subjects with a history of excised or treated basal
cell carcinoma or fewer than 3 squamous cell carcinomas are eligible to participate in
this study.
Key Exclusion Criteria: Part 2
- Subjects who did not complete study treatment in Part 1/Week 72 Visit
- Subjects who have a duration >12 weeks between their Part 1/Week 72 Visit and Part
2/Day 1.
- Contraindications to MRI, for example, presence of pacemakers or other implanted metal
devices (excluding dental braces), an allergy to Gd, renal impairment, or
claustrophobia that cannot be medically managed.
- History of human immunodeficiency virus or other immunodeficient conditions not
related to DMT treatment.
- History of malignancy unless enrollment is approved by the Sponsor; subjects with a
history of excised or treated basal cell carcinoma or fewer than 3 squamous cell
carcinomas are eligible to participate in this study.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
-
Plus d’informations sur l’étude
Date d’enregistrement de l’étude
17 juil. 2017
Intégration du premier participant
14 nov. 2017
Statut de recrutement
Terminated
Titre scientifique
(Source de données: WHO)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Optional Open-Label Extension in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies
Type d’étude
(Source de données: WHO)
Interventional
Conception de l’étude
(Source de données: WHO)
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Phase
(Source de données: WHO)
Phase 2
Points finaux primaires
(Source de données: WHO)
Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs);Overall Response Score
Points finaux secondaires
(Source de données: WHO)
Percentage of Participants with 12-week Confirmed Improvement in at least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND;Percentage of Participants with 12-week Confirmed Improvement in at least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, 9HPT-ND, or 3-Second Paced Auditory Serial Addition Test (PASAT-3);Percentage of Participants with 12-week Confirmed Improvement in at least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND, and without confirmed worsening in any of the 4 assessments during the 72 weeks of the study;Percentage of Participants with 12-week Confirmed Improvement in at least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, 9HPT-ND, and Symbol Digit Modalities Test (SDMT);Percentage of Participants with 12-week Confirmed Improvement in at least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND (20% thresholds for T25FW and 9HPT);Overall Response Score;Percentage of Participants with 24-week Confirmed Improvement in at least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND;Percentage of Participants with 24-week Confirmed Improvement in at least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, 9HPT-ND, or 3-Second Paced Auditory Serial Addition Test (PASAT-3);Percentage of Participants with 24-week Confirmed Improvement in at least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND, and without confirmed worsening in any of the 4 assessments during the 96 weeks of the study;Percentage of Participants with 24-week Confirmed Improvement in at least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, 9HPT-ND, and Symbol Digit Modalities Test (SDMT);Percentage of Participants with 24-week Confirmed Improvement in at least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND (20% thresholds for T25FW and 9HPT);Percentage of Participants with Potentially Clinically Significant Abnormal Laboratory Values;Percentage of Participants with Potentially Clinically Significant Electrocardiogram (ECG) Values;Percentage of Participants with Potentially Clinically Significant Abnormal Vital Signs Values;Columbia Suicide Severity Rating Scale (C-SSRS) Score;Percentage of Participants with Potentially Clinically Significant Abnormal Weight Values
Contact pour informations
(Source de données: WHO)
Please refer to primary and secondary sponsors
Résultats de l’étude
(Source de données: WHO)
Résumé des résultats
pas encore d’informations disponibles
Lien vers les résultats dans le registre primaire
pas encore d’informations disponibles
Informations sur la disponibilité des données individuelles des participants
pas encore d’informations disponibles
Lieux de réalisation des études
Lieux de réalisation des études en Suisse
(Source de données: BASEC)
Aarau, Bâle, Berne, Lugano, Zurich
Pays où sont réalisées les études
(Source de données: WHO)
Australia, Belgium, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom, United States
Contact pour plus d’informations sur l’étude
Données sur la personne de contact en Suisse
(Source de données: BASEC)
Dr. Claudio Gobbi
+41 91 811 6921
claudio.gobbi@eoc.ch
Contact pour des informations générales
(Source de données: WHO)
Medical Director
Biogen
Contact pour des informations scientifiques
(Source de données: WHO)
Medical Director
Biogen
Autorisation de la commission d’éthique (Source de données: BASEC)
Nom de la commission d’éthique chargée de l’autorisation (dans le cas d’études multicentriques, uniquement la commission directrice)
Comitato etico cantonale Ticino
Date d’autorisation de la commission d’éthique
30.10.2017
Plus de numéros d’identification d’étude
Numéro d’identification de l’étude de la commission d’éthique (BASEC-ID)
(Source de données: BASEC)
2017-01614
Secondary ID (Source de données: WHO)
2017-001224-22
215MS202
Retour à la vue d’ensemble